A Glimpse of necroptosis and diseases

Ming Yang; Wei Chen; Liyu He; Di Liu; Li Zhao; Xi Wang

doi:10.1016/j.biopha.2022.113925

A Glimpse of necroptosis and diseases

Biomed Pharmacother. 2022 Dec:156:113925. doi: 10.1016/j.biopha.2022.113925. Epub 2022 Oct 27.

Authors

Ming Yang¹, Wei Chen², Liyu He², Di Liu², Li Zhao³, Xi Wang⁴

Affiliations

¹ Department of Nutrition, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China.
² Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China.
³ Department of Reproduction and Genetics, the First Affiliated Hospital of Kunming Medical University, Kunming, China.
⁴ Department of Nutrition, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. Electronic address: 4011183@csu.edu.cn.

PMID: 36411617
DOI: 10.1016/j.biopha.2022.113925

Abstract

Programmed cell death plays an important role in maintaining homeostasis. Necroptosis is a type of programmed cell death that has been recently discovered. It is mediated by RIPK1, RIPK3, and MLKL, and is characterized by necrotic cell morphology. Interestingly, the abnormal activation of necroptosis could lead to inflammation and a variety of diseases. In this study, we reviewed the molecular mechanism underlying necroptosis, and discuss its role in the pathogenesis of various diseases. Finally, we summarize several current inhibitors of necroptosis and discuss the potential of targeting necroptosis as a therapeutic strategy for various diseases.

Keywords: Inflammation; MLKL; Necroptosis; Programmed cell death; RIPK1.

Publication types

Review

MeSH terms

Apoptosis
Humans
Inflammation / pathology
Necroptosis*
Necrosis / pathology
Protein Kinases* / metabolism

Substances

Protein Kinases